ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/medical-oncology/upper-gastrointestinal
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Gastrointestinal (Upper)
70
trial(s) found.
NCT07026279
Advanced
Phase 1 / Phase 2
Not yet recruiting
A Phase 1b/2a, Multicenter, Open Label Study of the Safety, Efficacy and Pharmacokinetics of Narmafotinib in Combination With Modified FOLFIRINOX in Pancreatic Cancer Patients (
AMP945-PC-202
)
FAK inhibitor
Pancreatic cancer
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
VIC
3121 - Richmond - Epworth Freemasons Hospital
NCT06926075
Advanced
Phase 1
Not yet recruiting
An Adaptive Phase I/II Study of Kesonotide, a Novel hGIIA-vimentin Inhibitor, in Participants With Solid Tumours (
ADVICE
)
hGIIA-vimentin inhibitor
Breast cancer
Glioblastoma
Lung cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Skin cancer
NCT06921837
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, First-in-Human, Dose Escalation and Expansion Study of BDC-4182 as a Single Agent in Patients With Advanced Gastric and Gastroesophageal Cancer (
BBI-4182-101
)
anti-CLDN18.2 immune-stimulating antibody conjugate,TLR7/8 agonist
Adenocarcinoma
Gastric cancer
Gastroesophageal junction adenocarcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
QLD
4575 - Birtinya - Sunshine Coast University Hospital
NCT06910657
Advanced
Phase 1
Not yet recruiting
A First-in-human, Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Evidence of Antitumor Activity of IDOV-Immune in Adult Participants With Advanced Solid Tumors (
VM-002-101
)
oncolytic virus,undisclosed mechanism
Bladder cancer
Breast cancer
Cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Gastric cancer
Head and neck cancer
Hepatocellular carcinoma
Lung cancer
Melanoma
Oesophageal cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Sarcoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
NCT06789172
Advanced
Phase 1
Recruiting
A Phase 1, Open-label, Multicenter, Dose-escalation and Cohort Expansion Study of OKN4395, a Triple Antagonist of EP2, EP4, and DP1 Prostanoid Receptors, as Monotherapy and in Combination With Pembrolizumab, in Patients With Advanced Solid Tumors (
INVOKE
)
anti-PD-1 monoclonal antibody
prostaglandin EP2/EP4/DP1 receptor inhibitor
Colorectal cancer
Dedifferentiated liposarcoma
Fibrosarcoma
Head and neck squamous cell carcinoma
Non-small cell lung cancer
Pancreatic adenocarcinoma
Sarcoma
Solid tumour
Solitary fibrous tumour
Undifferentiated pleomorphic sarcoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
WA
6009 - Nedlands - Linear Clinical Research
NCT06764875
Advanced
Phase 3
Recruiting
A Randomized, Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan Versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First Line Treatment of HER2-positive Gastric Cancer (ARTEMIDE-Gastric01) (
D702AC00001
)
anti-ERBB2 antibody-drug conjugate
anti-ERBB2 monoclonal antibody
anti-PD-1 monoclonal antibody
bispecific PD-1/TIGIT antibody
Gastroesophageal junction adenocarcinoma
HER2-positive gastric cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06617169
Radonc
Phase 1
Recruiting
Open Label, Phase 1a, Dose-Escalation Study Evaluating the Safety of Fractionated MNPR-101-PCTA-177Lu Dosing in the Treatment of Solid Tumor Cancers (
MNPR101-Lu-1-01
)
177Lu-anti-uPAR radioconjugate
Bladder cancer
Colorectal cancer
Gastric cancer
Lung cancer
Ovarian cancer
Pancreatic cancer
Solid tumour
Triple-negative breast cancer
Urothelial carcinoma
VIC
3051 - North Melbourne - Melbourne Theranostic Innovation Centre
NCT06608927
Advanced
Phase 3
Recruiting
A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Treatment-Naive Metastatic Pancreatic Ductal Adenocarcinoma (
PRISM-1
)
CD73 inhibitor
placebo
Pancreatic adenocarcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2500 - Wollongong - Wollongong Hospital
VIC
3168 - Clayton - Monash Medical Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06599502
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0022 Monotherapy and in Combination With Anti-cancer Agents in Participants With Tumours Harbouring a KRASG12D Mutation (
ALAFOSS-01
)
KRAS G12D inhibitor
Colorectal cancer
Non-small cell lung cancer
Pancreatic adenocarcinoma
Solid tumour
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT06585488
Advanced
Phase 1
Recruiting
A Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-53038, a Pan-KRAS Inhibitor, as Monotherapy or in Combinations in Patients With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplifications (
BGB-53038-101
)
pan-KRAS inhibitor
Cancer
Colorectal cancer
Gastric cancer
Non-squamous non-small-cell lung cancer
Oesophageal adenocarcinoma
Pancreatic adenocarcinoma
Solid tumour
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06581432
Advanced
Phase 2
Recruiting
Beamion PANTUMOR-1: A Phase II, Multicentre, Multicohort, Open-label Trial to Evaluate the Efficacy and Safety of Oral Zongertinib (BI 1810631) for the Treatment of Selected HER2-mutated or Overexpressed/Amplified Solid Tumours (
1479-0009
)
ERBB2 inhibitor,second generation
Breast cancer
Cervical cancer
Gastroesophageal junction adenocarcinoma
NOT Squamous non-small-cell lung cancer
Non-small cell lung cancer
Urothelial carcinoma
Uterine serous carcinoma
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2109 - North Ryde - Macquarie University Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT06533332
Advanced
Phase 1
Recruiting
A First-in-Human, Phase 1 Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy Study of Escalating Doses of ERX-315 in Participants With Advanced Solid Tumors (
ERX-315-101
)
benzamide,ER alpha-targeting
Breast cancer
Endometrial cancer
Hepatocellular carcinoma
Ovarian cancer
Pancreatic cancer
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2109 - North Ryde - Macquarie University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT06501625
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1b/2, Safety Lead-in and Dose-Expansion, Open Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Activity of Ivosidenib in Combination With Durvalumab and Gemcitabine/Cisplatin as First-line Therapy in Participants With Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation (
S095031-210
)
IDH1 R132 inhibitor
anti-PD-L1 monoclonal antibody
antimetabolite
platinum-based antineoplastic agent
Cholangiocarcinoma
VIC
3004 - Melbourne, Southbank - Alfred Health
NCT06478693
Advanced
Phase 1
Recruiting
A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including Hepatocellular Carcinoma (
MTX-GPC3-303
)
GPC3-targeting lipid-nanoparticle CAR mRNA
GPC3-targeting lipid-nanoparticles
Hepatocellular carcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
QLD
4102 - Woolloongabba - Integrated Clinical Oncology Network (ICON) Pty Ltd
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06467357
Advanced
Phase 3
Recruiting
DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig Versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer (
DESTINY-BTC01
)
anti-ERBB2 antibody-drug conjugate
anti-PD-L1 monoclonal antibody
antimetabolite
bispecific PD-1/TIGIT antibody
platinum-based antineoplastic agent
Biliary tract cancer
NSW
2139 - Concord - Concord Repatriation General Hospital
VIC
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06441747
Advanced
Phase 2
Recruiting
Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (
BIL-PPP
)
PARP inhibitor
anti-PD-L1 monoclonal antibody
Cholangiocarcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT06428409
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers (
9999-02A
)
anti-Trop2 antibody-drug conjugate
Biliary tract cancer
Colorectal cancer
Pancreatic adenocarcinoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
WA
6009 - Nedlands - One Clinical Research
NCT06427941
Advanced
Phase 1
Recruiting
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B2033, Alone or in Combination With Tislelizumab, in Participants With Selected Advanced or Metastatic Solid Tumors (
BGB-B2033-101
)
anti-GPC3 monoclonal antibody
anti-PD-1 monoclonal antibody
Gastric cancer
Hepatocellular carcinoma
Solid tumour
Squamous non-small-cell lung cancer
Yolk sac tumour
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06400472
Advanced
Phase 1
Recruiting
A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an Antibody-Drug Conjugate Targeting Folate Receptor α-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors
anti-FR-alpha antibody-drug conjugate
Cervical cancer
Colorectal cancer
Endometrial cancer
Non-small cell lung cancer
Ovarian cancer
Pancreatic cancer
Triple-negative breast cancer
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT06360354
Advanced
Phase 1
Recruiting
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 in Combination With Other Therapies in Subjects With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous MTAP-deletion
PRMT5 inhibitor
Pancreatic cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - GenesisCare North Shore Private Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT06290505
Radonc
Phase 2
Recruiting
PALEO
: Phase II Clinical Trial of Chemoradioimmunotherapy for the ALleviation of oEsOphageal Cancer Complications
Carboplatin
Durvalumab
Paclitaxel
Radiotherapy
anti-PD-L1 monoclonal antibody
cancer therapy
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cytotoxic chemotherapy
immune checkpoint blockade
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,PD-L1-targeting
platinum-based antineoplastic agent
taxane
Oesophageal cancer
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2640 - Albury - Border Medical Oncology Research Unit
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3066 - Epping - Northern Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06257264
Advanced
Phase 1
Recruiting
A Phase 1a/1b Study of BG-68501, a Selective CDK2 Inhibitor, in Participants With Advanced Solid Tumors (
BG-68501-101
)
CDK2 inhibitor
Bladder cancer
Breast cancer
Endometrial cancer
Gastric cancer
Gastroesophageal cancer
Ovarian cancer
Prostate cancer
Small-cell lung cancer
Solid tumour
Triple-negative breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - GenesisCare North Shore Private Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06252753
Curative
Recruiting
An Observational Multi Center Study to Evaluate Real World Treatment Outcomes of Durvalumab Based Regimens in Hepatobiliary Cancers (
LIVER-R
)
anti-PD-L1 monoclonal antibody
Hepatobiliary cancer
ACT
2605 - Garran - The Canberra Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06242470
Advanced
Phase 1
Recruiting
A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors (
CP-MGC026-01
)
anti-B7H3 antibody-drug conjugate
Bladder cancer
Breast cancer
Cancer
Castrate-resistant prostate cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Endometrial cancer
Gastric cancer
Gastroesophageal cancer
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Melanoma
Non-small cell lung cancer
Ovarian cancer
Pancreatic cancer
Platinum resistant ovarian cancer
Sarcoma
Small-cell lung cancer
Solid tumour
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT06238479
Advanced
Phase 1
Recruiting
A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Recurrent, Advanced or Metastatic Solid Tumors (
EXCEED
)
anti-NECTIN4 antibody-drug conjugate
Bladder cancer
Cervical cancer
Head and neck squamous cell carcinoma
Non-small cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Renal pelvis cancer
Solid tumour
Triple-negative breast cancer
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT06219941
Advanced
Phase 2
Recruiting
A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Tumours Expressing Claudin 18.2 (CLARITY-PanTumour01) (
D9800C00001
)
anti-CLDN18.2 antibody-drug conjugate
Biliary tract cancer
Cancer
Gastric cancer
Pancreatic adenocarcinoma
NSW
2031 - Randwick - Prince of Wales Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06172478
Advanced
Phase 2
Recruiting
HERTHENA-PanTumor01 (
U31402-277
): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors
anti-ERBB3 antibody-drug conjugate
Bladder cancer
Cervical cancer
Endometrial cancer
Gastric cancer
Gastroesophageal cancer
Head and neck squamous cell carcinoma
High-grade serous ovarian cancer
Melanoma
Oesophageal cancer
Pancreatic adenocarcinoma
Prostate adenocarcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3168 - Clayton - Monash Medical Centre
QLD
4032 - Chermside - Icon Cancer Care Chermside
4812 - Hyde Park - Icon Cancer Centre Townsville
TAS
7000 - Hobart - ICON Cancer Care Hobart
NCT06157892
Advanced
Phase 2
Recruiting
A Phase 1b/2 Open-Label Study of Disitamab Vedotin in Combination With Other Anticancer Therapies in Solid Tumors (
SGNDV-004
)
anti-ERBB2 antibody-drug conjugate
Breast cancer
Gastric cancer
Gastroesophageal junction adenocarcinoma
HER2-low breast cancer
HER2-positive breast cancer
Triple-negative breast cancer
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
NA
NA
NCT06116136
Advanced
Phase 1 / Phase 2
Recruiting
Open Label, Non-randomized, Phase 1b/2 Trial Investigating the Safety, Tolerability, and Antitumor Activity of S095029 (Anti-NKG2A Antibody) as a Part of Combination Therapy in Participants With Locally Advanced and Unresectable or Metastatic MSI-H/dMMR Gastro-esophageal Junction /Gastric Cancer (
CL1-95029-002
)
anti-NKG2A monoclona antibody
Cancer
Gastric cancer
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT06109779
Curative
Phase 3
Recruiting
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01) (
D7025C00001
)
bispecific PD-1/TIGIT antibody
placebo
Biliary tract cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3168 - Clayton - Monash Medical Centre
3021 - St Albans - Western Health - Sunshine Hospital (WITHDRAWN)
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06084481
Advanced
Phase 1
Recruiting
A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications (
M24-427
)
anti-cMET antibody-drug conjugate
Biliary tract cancer
Breast cancer
Epithelial Ovarian Cancer
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Oesophageal squamous cell carcinoma
Pancreatic adenocarcinoma
Triple-negative breast cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT05891171
Advanced
Phase 1
Recruiting
A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants With Advanced Malignancies (
ARC-25
)
anti-CD39 monoclonal antibody
Bladder cancer
Cancer
Cervical cancer
Clear cell renal cell carcinoma
Gastric cancer
Head and neck squamous cell carcinoma
Non-small cell lung cancer
Oesophageal cancer
Ovarian cancer
Triple-negative breast cancer
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5011 - Woodville South - The Queen Elizabeth Hospital
NCT05872295
Advanced
Phase 1
Recruiting
A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS014, a HER2-Targeting Antibody Drug Conjugate (ADC), in Participants With Advanced HER2+ Solid Tumors (
IKS014-01
)
anti-ERBB2 antibody-drug conjugate
Breast cancer
Gastric cancer
Gastroesophageal junction adenocarcinoma
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3199 - Frankston - Peninsula Health Frankston Hospital
WA
6009 - Nedlands - Linear Clinical Research
NCT05727176
Advanced
Phase 2
Recruiting
Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements (
FOENIX-CCA4
)
pan-FGFR inhibitor,irreversible
Cholangiocarcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT05706129
Radonc
Phase 1 / Phase 2
Recruiting
A Multicenter, Open-Label, Non-Randomized Phase 1/2 Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Patients With Unresectable Locally Advanced or Metastatic Solid Tumors (
Debio-0228-101
)
Bladder cancer
Clear cell renal cell carcinoma
Colorectal cancer
Head and neck cancer
Pancreatic adenocarcinoma
Squamous non-small-cell lung cancer
Triple-negative breast cancer
Urothelial carcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT05581004
Advanced
Phase 1
Recruiting
A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors (
GO43860
)
unknown drug class
Gastric cancer
Head and neck squamous cell carcinoma
Melanoma
Non-small cell lung cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT05498597
Advanced
Phase 1
Recruiting
First-in-Human, Phase 1 Study of AMT-151, an Anti-Folate Receptor Alpha Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours (
AMT-151-01
)
anti-FR-alpha antibody-drug conjugate
Adenocarcinoma
Cancer
Carcinoma
Endometrial cancer
Endometrial clear cell carcinoma
Endometrial endometrioid carcinoma
Lung adenocarcinoma
Ovarian cancer
Ovarian clear cell carcinoma
Ovarian endometrioid adenocarcinoma
Pancreatic adenocarcinoma
Pleural mesothelioma
Solid tumour
Triple-negative breast cancer
Uterine serous carcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - One Clinical Research
NCT05466799
Radonc
Phase 2
Recruiting
An Open-label, Multi-centre, Randomized Study of TaRgeted Intratumoural Placement of P-32 (OncoSil™) in Addition to FOLFIRINOX Chemotherapy vs FOLFIRINOX Alone in Patients With Unresectable Locally Advanced Pancreatic Adenocarcinoma. (
TRIPP-FFX
)
brachytherapy
Pancreatic cancer
VIC
3121 - Richmond - Epworth Freemasons Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT05411133
Advanced
Phase 1
Recruiting
A Phase 1, First-in-human Study of Cabotamig (ARB202), Bispecific Antibody to CDH17 and CD3 in Advanced Gastrointestinal Malignancies (
A001
)
bispecific T-cell engager,CDH17-targeting
Cholangiocarcinoma
Colorectal adenocarcinoma
Gastric cancer
Gastrointestinal cancer
Hepatocellular carcinoma
Oesophageal adenocarcinoma
Pancreatic cancer
NSW
2217 - Kogarah - St George Private Hospital
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT05254171
Advanced
Phase 2 / Phase 3
Recruiting
A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma (
ASPIRE
)
antimetabolite
placebo
polyamine analogue
taxane
Pancreatic adenocarcinoma
Pancreatic cancer
NSW
2485 - Tweed Heads - The Tweed Hospital (WITHDRAWN)
ACT
2605 - Garran - The Canberra Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
SA
5037 - Glandore - Ashford Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05245968
Advanced
Phase 1
Recruiting
A Phase 1 Study of TAS-116 (Pimitespib) in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumor
BCR-ABL1 inhibitor,first generation
HSP90 inhibitor
KIT inhibitor
PDGFRA inhibitor
Gastrointestinal stromal tumour
VIC
3004 - Melbourne, Southbank - Alfred Health
SA
5035 - Ashford - Flinders Medical Centre, Ashford Cancer Centre Research
NCT05169177
Radonc
Recruiting
Radio-opaque Contrast Agents for Liver Cancer Targeting With KIM During Radiation Therapy (
ROCK-RT
)
radiotherapy
Hepatocellular carcinoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT05141149
Advanced
Phase 1 / Phase 2
Recruiting
A First in Human, Phase 1/2a, Multicentre, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of PBP1510 in Patients With Advanced/Metastatic Pancreatic Cancer (
PAUF-I
)
Gemcitabine
antimetabolite
cancer therapy
cytotoxic chemotherapy
Pancreatic cancer
VIC
3168 - Clayton - Monash Medical Centre
NCT05123482
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/IIa Multi-center, Open-label Master Protocol Dose Escalation and Expansion Study of AZD8205 as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors (BLUESTAR) (
D6900C00001
)
anti-B7H4 antibody-drug conjugate
Biliary tract cancer
Breast cancer
Endometrial cancer
Ovarian cancer
Squamous non-small-cell lung cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (WITHDRAWN)
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05094336
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors (
MTAPESTRY-101
)
PRMT5 inhibitor
taxane
Gastric cancer
Gastroesophageal cancer
Pancreatic adenocarcinoma
Squamous non-small-cell lung cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3002 - East Melbourne - Epworth Freemasons
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
NCT05086692
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors (
ABILITY-1
)
IL-2 superkine
Acral lentiginous melanoma
Bladder cancer
Cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Cutaneous basal cell carcinoma
Cutaneous melanoma
Cutaneous squamous cell carcinoma
Endometrial cancer
Endometrial carcinoma
Epithelial Ovarian Cancer
Fallopian tube cancer
Gastric cancer
Gastroesophageal junction adenocarcinoma
Head and neck squamous cell carcinoma
Melanoma
Merkel cell carcinoma
Mucosal melanoma
Non-melanoma skin cancer
Non-squamous non-small-cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic adenocarcinoma
Pleural mesothelioma
Primary peritoneal serous carcinoma
Skin cancer
Solid tumour
Squamous non-small-cell lung cancer
Triple-negative breast cancer
dMMR solid cancer
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2109 - North Ryde - Macquarie University Hospital
QLD
4120 - Greenslopes - Greenslopes Private Hospital
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic
NCT04924075
Advanced
Phase 2
Recruiting
A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α Related Genetic Alterations (
6482-015
)
HIF2a inhibitor
Gastrointestinal stromal tumour
Pancreatic neuroendocrine tumour
Paraganglioma
Phaeochromocytoma
Solid tumour
NSW
2031 - Randwick - Prince of Wales Hospital
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
NCT04895709
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors (
CA052-002
)
anti-CCR8 monoclonal antibody
anti-PD-1 monoclonal antibody
taxane
Cervical cancer
Clear cell renal cell carcinoma
Gastroesophageal junction adenocarcinoma
Head and neck squamous cell carcinoma
Melanoma
Microsatellite stable colorectal cancer
Non-small cell lung cancer
Ovarian cancer
Pancreatic adenocarcinoma
Triple-negative breast cancer
Urothelial carcinoma
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2170 - Liverpool - Liverpool Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Nedlands - One Clinical Research
NCT04644068
Advanced
Phase 1 / Phase 2
Recruiting
A Modular Phase I/IIa, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (
PETRA
)
PARP1-selective inhibitor
Biliary tract cancer
Bladder cancer
Breast cancer
Cervical cancer
Colorectal cancer
Endometrial cancer
Gastric cancer
Non-small cell lung cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Small-cell lung cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT04524871
Advanced
Phase 1 / Phase 2
Recruiting
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (
Morpheus-Liver
)
ADG126
Atezolizumab
Bevacizumab
HIF2a inhibitor
NKT2152
PPAR-alpha inhibitor
TPST-1120
Tiragolumab
Tobemstomig
Tocilizumab
anti-CTLA4 monoclonal antibody
anti-IL-6 monoclonal antibody
anti-PD-L1 monoclonal antibody
anti-TIGIT monoclonal antibody
anti-VEGF monoclonal antibody
bispecific PD-1/LAG3 antibody
cancer therapy
cancer therapy,CTLA4-targeting
cancer therapy,HIF2a-targeting
cancer therapy,IL-6-targeting
cancer therapy,LAG3-targeting
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,PPAR-alpha-targeting
cancer therapy,TIGIT-targeting
cancer therapy,VEGF-targeting
immune checkpoint blockade
immune checkpoint blockade,CTLA4-targeting
immune checkpoint blockade,LAG3-targeting
immune checkpoint blockade,PD-1-targeting
immune checkpoint blockade,PD-L1-targeting
immune checkpoint blockade,TIGIT-targeting
immuno-oncology therapy,CTLA4-targeting
immuno-oncology therapy,IL-6-targeting
immuno-oncology therapy,LAG3-targeting
immuno-oncology therapy,PD-1-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,TIGIT-targeting
immuno-oncology therapy,VEGF-targeting
Hepatocellular carcinoma
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT04429542
Advanced
Phase 1
Recruiting
First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGFβ Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-Driven Advanced Solid Tumors (
BCA101X1101
)
bifunctional EGFR/TGF-beta fusion protein
Anal squamous cell carcinoma
Carcinoma
Colorectal cancer
Cutaneous squamous cell carcinoma
Epithelial Ovarian Cancer
Head and neck cancer
Head and neck squamous cell carcinoma
Pancreatic cancer
Squamous cell carcinoma
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT03505229
Radonc
NA
Recruiting
Stereotactic Body Radiotherapy [SBRT] for High Risk Localised Pancreatic Cancer: a Phase II Study of the Department of Radiation Oncology Royal North Shore Hospital (
Span-C
- SBRT for Pancreatic Cancer)
radiotherapy
Pancreatic cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
NCT03175224
Advanced
Phase 2
Recruiting
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (
SPARTA
)
MET inhibitor,type 1
Cancer
Central nervous system cancer
Colon adenocarcinoma
Gastric cancer
Gastroesophageal junction adenocarcinoma
Glioblastoma
Kidney cancer
Lung cancer
MET:alteration
MET:fusion
Non-small cell lung cancer
Pancreatic cancer
Solid tumour
Thyroid cancer
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
NCT02628067
Advanced
Phase 2
Recruiting
A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158) (
KEYNOTE-158
)
anti-PD-1 monoclonal antibody
Anal cancer
Biliary tract cancer
Cancer
Cervical cancer
Cholangiocarcinoma
Colorectal cancer
Endometrial cancer
Endometrial carcinoma
Lung carcinoid tumour
Mesothelioma
Neuroendocrine tumour
Pancreatic neuroendocrine tumour
Salivary gland cancer
Salivary gland carcinoma
Small-cell lung cancer
Solid tumour
Thyroid cancer
Vulval cancer
ACTRN12625000203459
Advanced
Phase 1 / Phase 2
Recruiting
An open-label, multicenter, Phase I/IIa study assessing the safety and efficacy of EGFR targeted EDVsTM carrying cytotoxic drug PNU-159682 plus concurrent immunomodulatory adjuvant non-targeted EDVs carrying a-galactosyl ceramide in subjects with advanced EGFR-expressing cancers who have failed second-line therapy or where first- and/or second-line therapy is not appropriate (EGFR EDV-D682/GC Trial) (
ENG19
)
EnGeneIC Dream Vector-nanocells-delivered,EGFR-targeting
Colorectal cancer
Kidney cancer
Lung cancer
Mesothelioma
Non-small cell lung cancer
Pancreatic adenocarcinoma
Solid tumour
Triple-negative breast cancer
NSW
2060 - North Sydney - Mater Hospital
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
ACTRN12624001345572
Curative
Phase 2
Not yet recruiting
DEFINERx050
: A Multicentre, Randomized, Open-Label Study of Atezolizumab (Anti-PD-L1 Antibody) Plus Bevacizumab (Anti-VEGF Antibody) as Neo-Adjuvant ImmunoTherapy Versus Active Surveillance in Hepatocellular Carcinoma Patients with high Onco-Fetal Characteristics Before Surgical Resection
anti-PD-L1 monoclonal antibody
anti-VEGF monoclonal antibody
Hepatocellular carcinoma
ACTRN12624001067561
Advanced
Not Applicable
Not yet recruiting
Evaluate the effectiveness of implementing a supportive care navigation tool for people diagnosed with pancreatic cancer.
Pancreatic cancer
SA
5042 - Bedford Park - Flinders Medical Centre
ACTRN12624000770561
Curative
Not yet recruiting
Survival and Patterns of Care in the Era of Chemo-, Radio-, and Immuno-Oncology for Gastroesophageal Junction Cancers - A multicentre cohort study (
SPACE-CRIO
)
Nivolumab
Radiotherapy
anti-PD-1 monoclonal antibody
cancer therapy
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
immune checkpoint blockade
immune checkpoint blockade,PD-1-targeting
immuno-oncology therapy,PD-1-targeting
Gastric adenocarcinoma
Gastric cancer
Gastroesophageal cancer
Gastroesophageal junction adenocarcinoma
ACTRN12624000588594
Advanced
Phase 2
Not yet recruiting
A Phase 2, Open-Label, Multicentre Study to Assess the Preliminary Efficacy and Safety of RXC004, in Patients with Advanced Pancreatic Cancer that have Progressed following Therapy with Current Standard of Care (
PORCUPINE2-Australian-Extension
)
PORCN inhibitor
Pancreatic cancer
ACTRN12624000005550
Curative
Phase 3
Recruiting
Efficacy of Neoadjuvant FOLFIRINOX in Resectable pancreatic cancer: An international multicenter prospective randomized, controlled trial (
NeoFOL-R
)
Filgrastim
Fluorouracil
Irinotecan
Leucovorin
Oxaliplatin
antimetabolite
cancer therapy
cytotoxic chemotherapy
fluoropyrimidine
platinum-based antineoplastic agent
topoisomerase inhibitor
Pancreatic cancer
ACTRN12623000798662
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of BOS-342 in Patients with Hepatocellular Carcinoma (
HCC
) and other GPC3-expressing Tumors
bispecific GPC3/4-1BB antibody
Cancer
Hepatocellular carcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2050 - Camperdown - Chris O'Brien Lifehouse
SA
5042 - Bedford Park - Flinders Medical Centre
ACTRN12623000223639
Advanced
Phase 1
Recruiting
A Phase 1 single-blind study evaluating LSTA1 in combination with durvalumab, gemcitabine and nab-paclitaxel as a first-line treatment in locally advanced pancreatic ductal adenocarcinoma (PDAC) (
iLSTA
)
anti-PD-L1 monoclonal antibody
antimetabolite
taxane
tumor-homing peptide iRGD
Pancreatic adenocarcinoma
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
ACTRN12622000302752
Radonc
Not Applicable
Not yet recruiting
Impact of intra-tumour injection of OncoSil (32P) on vascularity, stromal integrity and response to chemotherapy in locally advanced pancreatic carcinoma (
none
)
brachytherapy
Pancreatic cancer
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
ACTRN12622000180718
Curative
Not yet recruiting
Survival and Patterns of Care in the Era of FLOT-based Chemotherapy for Gastric and Gastroesophageal Adenocarcinoma (
SPACE-FLOT
): An international multicentre cohort study
Docetaxel
Fluorouracil
Leucovorin
Oxaliplatin
antimetabolite
cancer therapy
cytotoxic chemotherapy
fluoropyrimidine
platinum-based antineoplastic agent
taxane
Gastric adenocarcinoma
Gastric cancer
Gastroesophageal cancer
Gastroesophageal junction adenocarcinoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2200 - Bankstown - Bankstown-Lidcombe Hospital
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3011 - Footscray - Footscray Hospital
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NZ.9016 - Dunedin - Dunedin Hospital
ACTRN12621001444875
Radonc
Phase 2
Recruiting
A randomised controlled trial of Standard Of Care versus RadioAblaTion in Early Stage HCC (The SOCRATES HCC Study) (
The-SOCRATES-HCC-Study
)
Radiotherapy
cancer therapy
Hepatocellular carcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
ACTRN12617001571369
Radonc
Not yet recruiting
Effect of Stereotactic ablative body radiotherapy for Unresectable Pancreatic cancer with Endoscopic ultrasound inserted fiducial markers and concuRrent chemotherapy on survival rates: SUPER trial.
radiotherapy
Cancer
Pancreatic cancer
ACTRN12616000554460
Curative
Phase 1
Not yet recruiting
ACES
: Adjuvant Chemotherapy in Early stage oeSophageal cancer- a feasibility study
Cisplatin
Fluorouracil
antimetabolite
cancer therapy
cytotoxic chemotherapy
fluoropyrimidine
platinum-based antineoplastic agent
Oesophageal cancer
ACTRN12615000647538
Radonc
Not yet recruiting
Evaluating the efficacy of SIR-spheres in combination with chemotherapy for patients with pancreatic cancer with liver metastases (
nil
)
Gemcitabine
Nab-paclitaxel
Radiotherapy
antimetabolite
cancer therapy
cytotoxic chemotherapy
taxane
Pancreatic cancer
NCT03906331
Advanced
Approved for marketing
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
RET-selective inhibitor
RET inhibitor
Selpercatinib
cancer therapy
cancer therapy,RET-targeting
Breast cancer
Colon adenocarcinoma
Medullary thyroid cancer
Non-small cell lung cancer
Pancreatic cancer
Papillary thyroid cancer
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4032 - Chermside - The Prince Charles Hospital
WA
6009 - Nedlands - Linear Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT03900442
Advanced
Phase 1
Unknown status
Phase 1 Pharmacodynamic and Pharmacokinetic Study of the Geranylgeranyltransferase I Inhibitor PTX-100 (GGTI-2418) in Patients With Advanced Malignancies (
PTX-100-PD-012017
)
geranylgeranyl transferase inhibitor
Colorectal cancer
Gastric cancer
Multiple myeloma
Pancreatic adenocarcinoma
Peripheral T-cell lymphoma
VIC
3002 - East Melbourne - Epworth Freemasons
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (56)
Not yet recruiting (12)
Approved for marketing (1)
Unknown status (1)
Recruitment Country and State
VIC (45)
NSW (38)
WA (24)
SA (20)
QLD (17)
NZ (7)
ACT (3)
TAS (2)
Phase
Phase 1 (24)
Phase 1 / Phase 2 (16)
Phase 2 (14)
Phase 2 / Phase 3 (1)
Phase 3 (5)
Trial Type
Advanced (53)
Radonc (10)
Curative (7)
Cancer Therapy Class
PD-1/PD-L1
31%
PD-1
23%
PD-L1
13%
ERBB2
9%
TIGIT
7%
EGFR
4%
oestrogen axis
4%
GPC3
4%
PARP
4%
VEGF
4%
CLDN18.2
3%
KRAS
3%
Trop2
3%
FR-alpha
3%
PRMT5
3%
ER
3%
CTLA4
3%
MET
3%
PARP1-selective
3%
HIF2a
3%
FAK
1%
hGIIA-vimentin
1%
prostaglandin DP1 receptor
1%
prostaglandin EP2 receptor
1%
prostaglandin EP4 receptor
1%
CD73
1%
KRAS G12D
1%
ER alpha
1%
IDH1
1%
IDH1 R132
1%
CDK2
1%
CDK4
1%
CDK4 selective
1%
B7H3
1%
Nectin-4
1%
ERBB3
1%
DPD
1%
orotate phosphoribosyltransferase
1%
CD39
1%
FGFR
1%
FGFR1
1%
FGFR1/2/3
1%
FGFR2
1%
FGFR3
1%
FGFR4
1%
CDH17
1%
BCR-ABL1
1%
HSP90
1%
KIT
1%
PDGFR
1%
PDGFRA
1%
VEGFR
1%
B7H4
1%
IL-2
1%
CCR8
1%
IL-6
1%
LAG3
1%
PPAR-alpha
1%
PORCN
1%
RANK L
1%
4-1BB
1%
RET
1%
geranylgeranyl transferase
1%
Facility
3000 - Melbourne - Peter MacCallum Cancer Centre (13)
2050 - Camperdown - Chris O'Brien Lifehouse (12)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (12)
3168 - Clayton - Monash Medical Centre (11)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (9)
6150 - Murdoch - Fiona Stanley Hospital (9)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (9)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (8)
3004 - Melbourne, Southbank - Alfred Health (7)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (7)
4102 - Woolloongabba - Princess Alexandra Hospital (7)
5042 - Bedford Park - Flinders Medical Centre (6)
6009 - Nedlands - Linear Clinical Research (5)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (5)
2065 - St Leonards - GenesisCare North Shore Private Hospital (4)
2109 - North Ryde - Macquarie University Hospital (4)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (4)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (4)
3199 - Frankston - Peninsula Health Frankston Hospital (4)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (3)
3021 - St Albans - Western Health - Sunshine Hospital (3)
3002 - East Melbourne - Epworth Freemasons (3)
6009 - Nedlands - One Clinical Research (3)
5011 - Woodville South - The Queen Elizabeth Hospital (3)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (3)
2605 - Garran - The Canberra Hospital (3)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (3)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (3)
3121 - Richmond - Epworth Freemasons Hospital (2)
2500 - Wollongong - Wollongong Hospital (2)
2139 - Concord - Concord Repatriation General Hospital (2)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (2)
3066 - Epping - Northern Hospital (2)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (2)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (2)
2031 - Randwick - Prince of Wales Hospital (2)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (2)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (2)
3065 - Fitzroy - St Vincent's Hospital Melbourne (2)
3128 - Box Hill - Box Hill Hospital - Eastern Health (2)
4575 - Birtinya - Sunshine Coast University Hospital (1)
3051 - North Melbourne - Melbourne Theranostic Innovation Centre (1)
4102 - Woolloongabba - Integrated Clinical Oncology Network (ICON) Pty Ltd (1)
2640 - Albury - Border Medical Oncology Research Unit (1)
4032 - Chermside - Icon Cancer Care Chermside (1)
4812 - Hyde Park - Icon Cancer Centre Townsville (1)
7000 - Hobart - ICON Cancer Care Hobart (1)
NA
2217 - Kogarah - St George Private Hospital (1)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (1)
2485 - Tweed Heads - The Tweed Hospital (1)
5037 - Glandore - Ashford Cancer Centre (1)
5035 - Ashford - Flinders Medical Centre, Ashford Cancer Centre Research (1)
2031 - Randwick - Scientia Clinical Research Ltd (1)
4120 - Greenslopes - Greenslopes Private Hospital (1)
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic (1)
2170 - Liverpool - Liverpool Hospital (1)
2060 - North Sydney - Mater Hospital (1)
2200 - Bankstown - Bankstown-Lidcombe Hospital (1)
3011 - Footscray - Footscray Hospital (1)
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre (1)
5112 - Elizabeth Vale - Lyell McEwin Hospital (1)
7000 - Hobart - Royal Hobart Hospital (1)
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre (1)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
NZ.9016 - Dunedin - Dunedin Hospital (1)
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital (1)
4215 - Southport - Gold Coast University Hospital (1)
4032 - Chermside - The Prince Charles Hospital (1)
Cancer Type
Cancer
Gastrointestinal cancer
Solid tumour
Upper gastrointestinal cancer
Pancreatobiliary cancer
Pancreatic cancer
Thoracic cancer
Gastroesophageal cancer
Lung cancer
Respiratory tract cancer
Gastric cancer
Hepatobiliary cancer
Breast cancer
Non-small cell lung cancer
Gynaecological cancer
Oesophageal cancer
Colorectal cancer
Lower gastrointestinal cancer
Ovarian cancer
Exocrine pancreatic cancer
Pancreatic adenocarcinoma
Urogenital cancer
Head and neck cancer
HPV-related cancer
HPV16-positive cancer
Hepatocellular carcinoma
Viral-related cancer
Breast adenocarcinoma
Triple-negative breast cancer
Biliary tract cancer
Cervical cancer
Endometrial cancer
Gastric carcinoma
Gastroesophageal junction adenocarcinoma
Bladder cancer
Head and neck squamous cell carcinoma
Male genital cancers
Kidney cancer
Prostate cancer
Carcinoma
Clear cell renal cell carcinoma
Melanoma
Epithelial Ovarian Cancer
Cholangiocarcinoma
Squamous non-small-cell lung cancer
Urothelial carcinoma
Endometrial carcinoma
Neuroendocrine carcinoma
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
Mesothelioma
Colorectal adenocarcinoma
Endocrine gland cancer
Skin cancer
Sarcoma
Gastric adenocarcinoma
Non-squamous non-small-cell lung cancer
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
Ovarian adenocarcinoma
Thyroid cancer
Central nervous system cancer
Glioblastoma
Glioma
High-grade glioma
Malignant glioma
Neurological cancer
Adenocarcinoma
Oesophageal adenocarcinoma
Uterine serous carcinoma
High-grade serous ovarian cancer
Ovarian serous carcinoma
Prostate adenocarcinoma
Pleural mesothelioma
Gastrointestinal stromal tumour
Cutaneous squamous cell carcinoma
Non-melanoma skin cancer
Gastro-entero-pancreatic neuroendocrine tumour
Neuroendocrine tumour
Pancreatic neuroendocrine tumour
Anal cancer
Colon adenocarcinoma
Dedifferentiated liposarcoma
Fibrosarcoma
Liposarcoma
Soft tissue sarcoma
Solitary fibrous tumour
Undifferentiated pleomorphic sarcoma
HER2-positive gastric cancer
Germ cell tumour
Non-seminoma
Testicular cancer
Yolk sac tumour
Castrate-resistant prostate cancer
Platinum resistant ovarian cancer
Renal pelvis cancer
HER2-low breast cancer
HER2-negative breast cancer
HER2-positive breast cancer
Oesophageal squamous cell carcinoma
Endometrial adenocarcinoma
Endometrial clear cell carcinoma
Endometrial endometrioid carcinoma
Lung adenocarcinoma
Ovarian clear cell carcinoma
Ovarian endometrioid adenocarcinoma
Acral lentiginous melanoma
Biomarker-defined solid tumour
Cutaneous basal cell carcinoma
Cutaneous melanoma
Fallopian tube cancer
MSI-H/dMMR solid tumour
Merkel cell carcinoma
Mucosal melanoma
Peritoneal cancer
Primary peritoneal serous carcinoma
dMMR solid cancer
Adrenal cancer
Paraganglioma
Phaeochromocytoma
Microsatellite stable colorectal cancer
Non-microsatellite instability-high colorectal cancer
Anal squamous cell carcinoma
Squamous cell carcinoma
MET:alteration
MET:fusion
Lung carcinoid tumour
Salivary gland cancer
Salivary gland carcinoma
Vaginal and vulvar cancer
Vulval cancer
Differentiated thyroid carcinoma
Medullary thyroid cancer
Papillary thyroid cancer
Haematological malignancy
Lymphoma
Multiple myeloma
Non-Hodgkin's lymphoma
Peripheral T-cell lymphoma
Plasma cell disorder
T-cell lymphoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy